TransMedics Group (TMDX) Could Be 19% Undervalued If Its Growth Narrative Holds

TransMedics Group (TMDX) has drawn investor attention after recent trading left the stock around $78.64, with returns down over the past month but higher over the past three months and three years.

Short term momentum for TransMedics Group has faded, with the share price return down 5.76% over one day, 6.27% over the past week and 4.38% over the past month. At the same time, a 14.20% 90 day share price return and a 54.08% three year total shareholder return point to a stock where sentiment has swung lower recently after a much stronger run in prior years.

Scan beyond TransMedics Group and line up other healthcare names with sharper recent trends using the hand picked 35 healthcare AI stocks as a comparison set.

TransMedics Group has cooled off after a strong multi year run and a tough last year, which leaves a simple puzzle for investors: Is most of the upside already behind the stock, or is there still meaningful value on the table?

Most Popular Narrative: 19% Undervalued

Against the last close at $78.64, the most followed narrative pegs TransMedics Group's fair value at $97.30. This frames recent share price weakness as a potential valuation gap rather than a complete change in the story.

Expansion into new organ types (notably kidney) and next-generation product launches (Gen 3 OCS platforms for heart, lung, and liver) are expected to materially grow TransMedics' total addressable market, improve product mix, and support higher average selling prices, benefiting earnings and longer-term net margins.

See why 78 investors see TransMedics Group as 19% undervalued .

Result: Fair Value of $97.30 (UNDERVALUED)

Still, TransMedics Group faces real pressure if new OCS platforms underperform in trials or if European expansion stalls under tougher reimbursement and regulatory regimes.

Find out about the key risks to this TransMedics Group narrative .

Next Steps

That mix of optimism and recent weakness around TransMedics Group can pull you in either direction, so move quickly, review the full picture, and weigh the company's 1 or more potential rewards using the 4 key rewards .

Looking for more investment ideas beyond TransMedics Group?

If TransMedics Group has you thinking harder about where to put fresh capital next, do not leave that curiosity idle. Put it to work with focused idea lists.

• Target potential mispricings by scanning a 28 high quality undervalued stocks that pairs quality fundamentals with attractive entry points.

• Prioritise resilience by using a 31 resilient stocks with low risk scores curated for businesses with sturdier balance sheets and fewer red flags.

• Hunt for overlooked potential through a 19 high quality undiscovered gems that surfaces under followed companies with stronger financial profiles than their visibility suggests.